Develop a new drug for someone Who might be suffering somewhere in the world.
Let's open up new markets and revenue streams by predicting more than one promising indication for a drug candidate at the early development stage. We are a specialized discovery team with novel technologies and unique massive bio-pharmacological data resources for discovering hidden possibilities of drugs.
Two major causes of failure in clinical trials are lack of safety (~45% failure rate in Phase I) and efficacy (~65% failure rate in Phase II). A synergistic drug combination increases the efficacy of the therapeutic effect and reduces toxicity as a result of decreased dosage. Using our unique Multi-Strategy Drug Repositioning System, we will find the most synergistic drug partner that will target multiple pathological networks with your drug.
In the process of researching for orphan diseases, one may come across the problem of a lack of information. That's where we step in. We can predict the pathological networks and suggest suitable drugs for diseases, on which you may have limited knowledge.
Efficacy and mechanism of NDC-060 revealed… Improvement of donepezil side effectsDoctor Noah Biotech (CEO Lee Ji-hyun, Doctor Noah) announced on the 11th that the non-clinical study results of the donepezil combination drug 'NDC-060' were published in the international academic journal Journal of Alzheimer's Disease. The paper published this time is a paper that reveals the efficacy and mechanism of NDC-060, a combination drug that can improve the side effects caused by donepezil.Donepezil is the first drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's Dementia (AD), and helps improve cognitive function in dementia patients. It is the most commonly ...
MORE ABOUT US▶
https://apnews.com/press-release/globenewswire-mobile/clinical-trials-u-s-food-and-drug-administration-986611bb972abf76b6b83bad19b05dc8By DR.NOAH BIOTECH Inc.Published 8:17 PM GMT+9, September 2, 2024SEOUL, KOREA, Sept. 02, 2024 (GLOBE NEWSWIRE) -- DR.NOAH BIOTECH (hereafter DR.NOAH), an AI-driven innovative drug development company, announced on August 23 that it had received approval from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application for Phase 1 clinical trial of a new drug combination (NDC-011) for Amyotrophic Lateral Sclerosis (ALS).This Phase 1 clinical trial is planned to be conducted at a specialized clinical trial institution in ...
MORE ABOUT US▶
Dr. Noah Biotech’s phase 1 drug candidate for stroke patients submitted for an IND application as the first example developed by AI… Series B expected to be revealed this year On July 22, Dr. Noah Biotech submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phase 1 drug candidate, ‘NDC-002,’ that helps recover from stroke developed by the artificial intelligence (AI) platform. With the AI platform, this bio-venture has focused on the development of new drugs specialized in neurological disorders. If the company obtains an approval of the IND application, ‘NDC-002’ would be regarded as the first example of t ...
MORE ABOUT US▶
Dr. Noah Biotech’s phrase 1 drug candidate for stroke patients submitted for an IND application as the first example developed by AINew combinatory phrase 1 drug candidate, NDC-002, that helps reduce neuroinflammation and stimulate neuronal differentiationDr. Noah Biotech announced that it submitted an Investigational New Drug (IND) application to the Korea Food and Drug Administration (KFDA) to demonstrate its new phrase 1 drug candidate, ‘NDC-002’ that helps recover from stroke on July 22.The company said if it obtains an approval of the IND application, ‘NDC-002’ would be regarded as the first example of the new drug candidate developed by AI in Korea.Based on multiple mechanisms, th ...
MORE ABOUT US▶
[Interview of Bio CEO] CEO Jihyun Lee of DR.NOAH BIOTECH dreams of developing 'blockbuster'--going beyond the technology transfer of six pipelines[Medigate News Reporter Minji Seo] Neurological disorder is one of the complex disorders that are difficult to treat by controlling a single target. It is composed of complex mechanisms connected organically. A meaningful effect is achieved only by setting multiple targets. Considering such characteristics of the disorder, DR. NOAH BIOTECH is developing treatment with a strategy called 'combinatory drug.' The company is actively making use of the artificial intelligence (AI) platform developed to increase the efficiency of R&D pipelines.In add ...
MORE ABOUT US▶
AI allows the industry to save the time and costs of the new medicine development - competitive advantages in the marketDaewoong Pharmaceutical's subsidiary develops treatment for difficulty in hearing with an AI company specializing in new medicine developmentSK Chemical & Dr. Noah Biotech research and develop the AI new medicine together[Segye Biz = Correspondent Kim Min-ji] South Korea's pharmaceutical industry comes forward with new medicine development using artificial intelligence (AI) in full scale.If they use AI, they can drastically reduce the cost and time of research and development (R&D) for new medicine. The development of new medicine is a long-term project that requires more t ...
MORE ABOUT US▶
"Doctor Noah will realize the possibility of developing a new drug using AI technology in the field of rare diseases."Lee Ji-hyun, CEO of Dr. Noah Biotech, said during the interview at the headquarters in Suwon. Dr. Noah Biotech (from now on referred to as Dr. Noah) is an AI new drug development venture. In particular, Dr. Noah's technology focuses on the discovery of complex substances fast. They also strive to develop their own complex for neurological diseases.They received KRW 1.5 billion funding in pre-series A in 2018 and KRW 4.5 billion funding in series A last August. It also attracted KRW 1 billion investment from JLK, which specializes in AI drugs. They have a short company history ...
MORE ABOUT US▶
Build a pipeline for next-generation new medicine… Expected to develop treatments for incurable diseases through innovative new medicineDr. Noah Biotech (CEO Lee Ji-hyun), a company specializing in new medicine development based on artificial intelligence, announced on the 27th that it signed an "AI-based joint research and development agreement" with SK Chemicals.The main purpose of this agreement is to establish the pipeline of a next-generation new medicine through two companies’ cooperation and joint research based on the AI platform owned by Dr. Noah Biotech and ultimately develop an innovative complex drug.Dr. Noah Biotech is a startup that directly develops the treatment for neurolo ...
MORE ABOUT US▶
DR. NOAH BIOTECH CEO JI-HYUN LEE gave a presentation titled Designing Drug Combinations for Orphan Diseases at ‘THE AI KOREA 2020 Conference’ held online on 27th.In its introductory remark, Ms. Lee said, "Our effort to incorporate AI technology into pharmaceutical development to increase efficiency and shorten the development period has continued up to now. In the global market, biotech companies, equipped with AI technology, are rubbing shoulders with multinational pharmaceuticals to develop new drugs with great success by attracting investment worth tens of and hundreds of billions of won. The country already saw more than ten AI companies jumping into the competition to bring a new drug ...
MORE ABOUT US▶
Biospectator Journalist Jongwon JangBNH Investment, KB Investment, POSCO Capital, and T Investment as participants… R&D starting with stroke and amyotrophic lateral sclerosis medicine as well as DMD and SMADr. Noah Biotech has succeeded in attracting investments of 4.5 billion KRW for Series A. With these investments, Dr. Noah Biotech will complete preclinical studies on its leading products, stroke and amyotrophic lateral sclerosis (Lou Gehrig's disease) medicine, and will launch its first clinical trials next year. According to Dr. Noah Biotech on the 12th, KB Investment, POSCO Capital, and T Investment participated in the investment by taking over common shares under the lead of BN ...
MORE ABOUT US▶
(16229) 경기도 수원시 영통구 창룡대로 256번길 91, 에이스광교타워2 1208호
(16229) ACE Gwanggyo Tower2 1208Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
Copyright © 2017 DR.NOAH BIOTECH All rights reserved.
Email. contact@drnoahbiotech.com | Tel. +82.31.546.1519 | Fax. +82.31.546.1529
(16229) ACE Gwanggyo Tower2 1208Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
Copyright © 2017 DR.NOAH BIOTECH All rights reserved.
Email. contact@drnoahbiotech.com | Tel. +82.31.546.1519 | Fax. +82.31.546.1529
(16229)ACE Gwanggyo Tower2 1208Ho, 91, Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea
